Long-term therapeutic experience of humanized anti-IL-6 receptor monoclonal antibody (aIL-6R Mab) in systemic-onset juvenile idiopathic arthritis (So-JIA).

被引：0
|
作者：
Yokota, S
Imagawa, T
Miyamae, T
Mori, M
Nishimoto, N
Kishimoto, T
机构：
[1] Yokohama City Univ, Sch Med, Yokohama, Kanagawa 232, Japan
[2] Osaka Univ, Osaka, Japan
来源：
ARTHRITIS AND RHEUMATISM | 2004年 / 50卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S438 / S438
页数：1
相关论文
共 26 条
  • [1] Long-term treatment of systemic onset juvenile idiopathic arthritis (SO-JIA) with humanized anti-IL-6 receptor monoclonal antibody, tocilizumab (Actemra®)
    Yokota, S
    Miyamae, T
    Kurosawa, R
    Ozawa, R
    Imagawa, T
    Mori, M
    Nishimoto, N
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S725 - S725
  • [2] Catch-up growth in severe systemic-onset juvenile idiopathic arthritis: Long-term treatment with humanized anti-IL6 receptor monoclonal antibody
    Imagawa, T
    Miyamae, T
    Umebayashi, H
    Kurosawa, R
    Katakura, S
    Mori, M
    Nishimoto, N
    Yokota, S
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2004, 50 (09): : S91 - S92
  • [3] Phase II trial of anti-IL-6 receptor antibody (MRA) for children with systemic-onset juvenile idiopathic arthritis
    Yokota, S
    Miyamae, T
    Imagawa, T
    Iwata, N
    Katakura, S
    Mori, M
    Nishimoto, N
    Yoshizaki, K
    Woo, P
    Hirsch, R
    Kishimoto, T
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S429 - S429
  • [4] Long-term therapeutic efficacy of humanized anti-il 6-receptor antibody for systemic juvenile idiopathic arthritis.
    Yokota, S
    Miyamae, TK
    Imagawa, T
    Nishimoto, N
    Yoshizaki, K
    Mori, M
    Hirsch, R
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S479 - S479
  • [5] Therapeutic Efficacy of Humanized Recombinant Anti-Interleukin-6 Receptor Antibody in Children With Systemic-Onset Juvenile Idiopathic Arthritis
    Yokota, Shumpei
    Miyamae, Takako
    Imagawa, Tomoyuki
    Iwata, Naomi
    Katakura, Shigeki
    Mori, Masaaki
    Woo, Patricia
    Nishimoto, Norihiro
    Yoshizaki, Kazuyuki
    Kishimoto, Tadamitsu
    ARTHRITIS AND RHEUMATISM, 2005, 52 (03): : 818 - 825
  • [6] IL-6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis
    Yokota, S
    Miyamae, T
    Imagawa, T
    Mori, M
    ARTHRITIS RESEARCH & THERAPY, 2003, 5 (Suppl 3) : S22 - S23
  • [7] IL-6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis
    S Yokota
    T Miyamae
    T Imagawa
    M Mori
    Arthritis Res Ther, 5
  • [8] Therapeutic efficacy of humanized anti-IL-6-receptor antibody in systemic juvenile idiopathic arthritis.
    Yokota, S
    Miyamae, T
    Imagawa, T
    Nishimoto, N
    Yoshizaki, K
    Hirsch, R
    Mori, M
    ARTHRITIS AND RHEUMATISM, 2001, 44 (09): : S291 - S291
  • [9] Tocilizumab - A humanized anti-IL-6 receptor monoclonal antibody for the treatment of rheumatoid arthritis
    Schlesselman, Lauren S.
    Hussey, Aaron P.
    FORMULARY, 2008, 43 (08) : 272 - 279
  • [10] Anti-IL-6 receptor antibody therapy of a girl with severe systemic juvenile idiopathic arthritis.
    Yamazaki, T
    Agematsu, K
    Tanaka, M
    Nagumo, H
    Yasui, K
    Komiyama, A
    CLINICAL IMMUNOLOGY, 2002, 103 (03) : S81 - S81
123